Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver & Co who wrote (2716)	11/10/1997 10:19:00 PM
From: Izzy	Read Replies (1) of 6136

Dr. Oliver: Good post; I'm always receptive to new ideas. I am aware of there being multiple HIV strains in the same patient. My assumption has been that most, if not all, strains (excluding the obvious resistant ones) respond equally well to the present combo drugs, including the PIs, thru inhibition of the same replication process. But, of course, even staph/strept have become penicillin (methicillin, Vancomycin) resistant. Damn smart bugs! How do they do that? It looks like present day technology keeps finding new stuff that seems to muddy the water (at least from a clinical standpoint). Thanks for the info.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next